← Leaderboards
Eileen Klein
University Of Washington
$9,016,088
Attributed
$18,028,007
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
CDC$18,023,838 · 2
NIH$4,169 · 2
By mechanism
U01$18,023,838 · 2
M01$4,169 · 2
Top collaborators
- Janet A Englund14 shared
Most similar at University Of Washington
Same institution · by research overlap
- Margaret McLean Heitkemper$19,105,705
- Evan D Kharasch$17,406,013
- David Baker$22,630,205
- Valerie D Daggett$9,474,279
- Tamir Gonen$7,001,443
Others in their field
Top investigators on “Anxiety”
- Ned H Kalin · University Of Wisconsin-Madison$44,272,910
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$28,733,950
- Subhash C Pandey · University Of Illinois At Chicago$27,656,996
- Joseph E Robertson · Oregon Health & Science University$27,496,135
- John P Capitanio · University Of California Davis$25,742,389
- Raquel E Gur · University Of Pennsylvania$25,607,780
Research focus
AnxietyMidazolamHuman SubjectSensory DepressionHuman Therapy EvaluationCombination ChemotherapyFentanylOral AdministrationClinical ResearchDevicesDoseEffectivenessEmergency SituationFundingGrantInstitutionIrritantsLacerationMinorMucous MembraneNoseOralOral CavityPain
Grant awards (19)
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$2,082,196
U01 · FY2025 · IP
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$1,234,285
U01 · FY2024 · IP
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$2,749,994
U01 · FY2023 · IP
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$2,300,000
U01 · FY2023 · IP
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$1,933,284
U01 · FY2022 · IP
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$1,441,645
U01 · FY2021 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases$1,505,484
U01 · FY2020 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases$1,000,000
U01 · FY2019 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases$300,000
U01 · FY2019 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases$1,226,950
U01 · FY2018 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases$250,000
U01 · FY2018 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases$1,000,000
U01 · FY2017 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases$785,715
U01 · FY2016 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases$214,285
U01 · FY2016 · IP
IMPROVING SEDATION OF CHILDREN UNDERGOING PROCEDURES IN THE EMERGENCY DEPART$305
M01 · FY2007 · RR · contact PI
TRANSMUCOSAL FENTANYL &MIDAZOLAM IN LACERATION REPAIR$0
M01 · FY2002 · RR
TRANSMUCOSAL FENTANYL &MIDAZOLAM IN LACERATION REPAIR$0
M01 · FY2001 · RR
RANDOMIZED TRIAL OF ORAL TRANSMUCOSAL FENTANYL &ORAL MIDAZOLAM VS OR$3,864
M01 · FY2000 · RR
TRANSMUCOSAL FENTANYL &MIDAZOLAM IN LACERATION REPAIR$0
M01 · FY2000 · RR